RPG Life Sciences Ltd logo

RPG Life Sciences Ltd

RPGLIFE NSE

Key Fundamentals

MicrocapPharmaceuticalsHealthcare
Market Cap
₹4,379 Cr
Volatility
Moderate
P/E Ratio
36.46
EBITDA
₹173 Cr
Return on Equity
19.03%
Debt to Equity
0.03
Book Value
₹366.01
EPS
₹55.82
52W High
₹3,082
52W Low
₹1,733

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view RPG Life Sciences Ltd insights

42 extracted metrics + investor summaries across FY12–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

2
  • Company is almost debt free.
  • Company has been maintaining a healthy dividend payout of 28.8%

Weaknesses

3
  • Stock is trading at 7.21 times its book value
  • Debtor days have increased from 46.5 to 60.2 days.
  • Working capital days have increased from 44.6 days to 63.7 days

Growth Rate

Revenue Growth
10.06% ↗
Net Income Growth
-37.12% ↘
Cash Flow Change
-27.43% ↘
ROE
-44.90% ↘
ROCE
-43.50% ↘
EBITDA Margin (Avg.)
-8.97% ↘

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 11d ago
AI opinion · based on fundamentals
Risk medium

RPG Life Sciences Ltd is a nearly debt-free healthcare company with a market cap of ₹4,574 Cr trading at a PE of 38.4x and PB of 7.59x. The company has delivered a 5-year profit CAGR of 22% and maintained ROE averaging 23% over five years, though recent working capital efficiency has deteriorated with debtor days rising from 46.5 to 60.2 days.

Bull Case 8
  • Company is almost debt-free, providing significant financial flexibility and low interest cost burden
  • Consistent 5-year ROE of 23% indicates strong capital efficiency and durable competitive advantages in its niche
  • Compounded profit growth of 22% over 5 years outpaces revenue growth of 13%, reflecting improving operating leverage and margin expansion
  • 10-year compounded profit CAGR of 25% demonstrates a long track record of sustained earnings growth
  • Stock has delivered a 3-year CAGR of 38% and 5-year CAGR of 40%, reflecting strong market confidence in the business trajectory
  • Healthy dividend payout ratio of 28.8% with a yield of 0.86% shows shareholder-friendly capital allocation despite being a growth company
  • TTM sales growth of 12% and profit growth of 13% indicate continued momentum in the most recent period
  • 10-year compounded sales CAGR of 10% shows the company has consistently grown its topline across business cycles
Bear Case 8
  • Stock trades at 7.59x book value, a steep premium that leaves limited margin of safety if growth decelerates
  • PE of 38.4x is elevated relative to broader pharma sector averages, pricing in significant future growth expectations
  • Debtor days increased from 46.5 to 60.2 days, suggesting deteriorating collection efficiency or channel stuffing risk
  • Working capital days expanded from 44.6 to 63.7 days, indicating the business is requiring more capital to fund operations
  • Last year ROE declined to 19% from a 3-year average of 23%, signaling potential moderation in return profile
  • Market cap of ₹4,574 Cr with a small-to-mid cap profile carries higher liquidity risk and volatility compared to large-cap pharma peers
  • TTM profit growth of 13% is below the 5-year CAGR of 22%, suggesting a possible deceleration in earnings momentum
  • 3-year sales CAGR of 11% lags the 5-year profit CAGR of 22%, raising questions about sustainability of margin expansion

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 9d ago
Positives 4
  • API spinoff eyes ₹700 cr growth Jul 29

    Board approved slump sale of API business to a wholly owned subsidiary for ₹33.55 crore, aiming to raise up to ₹700 crore from investors for organic and inorganic growth in the API segment.

  • Q1FY26 profit up 16% YoY Jul 29

    Standalone net profit rose 16% YoY to ₹305.7 lakh for Q1FY26, with revenue growing 16-18.5% to ₹195.7 crore driven by pharmaceutical operations.

  • ₹24 per share dividend declared Jul 23

    Shareholders approved a ₹24 dividend per share and reappointed key directors at the 19th AGM held on July 23, 2026.

  • Naprosyn ES partnership launched Jul 13

    Partnered with Archerchem Healthcare to exclusively market and distribute Naprosyn ES in India, a first-of-its-kind Naproxen-Esomeprazole combination for long-term pain management with gastro-protection.

Neutral 2
  • VP Sales & Marketing retires Aug 1

    Samir Rane, Vice President of Sales & Marketing (Main Division), retired on July 31, 2026 due to superannuation with no immediate successor named.

  • Independent Director exits board Jul 27

    Ms. Zahabiya Khorakiwala ceased as Independent Director on July 26, 2026 after completing her second consecutive five-year term.

TL;DR: RPG Life Sciences is executing well with 16% YoY profit growth and a strategic API business spinoff targeting ₹700 crore in fresh investment. The ₹24 dividend and new product partnership signal management confidence. Key leadership departures (VP Sales, Independent Director) are routine but worth monitoring for succession clarity. The trend is improving with growth investments and strong quarterly results pointing to continued momentum.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
148
154
154
127
165
172
173
143
169
182
180
177
196
Expenses
116
116
116
106
126
126
124
118
133
143
140
144
152
Operating Profit
32
37
38
21
39
46
49
25
35
39
40
33
44
OPM %
22%
24%
25%
16%
24%
27%
28%
18%
21%
21%
22%
19%
22%
Other Income
2
2
2
2
2
-25
3
115
5
16
-5
13
4
Interest
0
0
0
0
0
0
0
0
0
0
0
0
1
Depreciation
4
4
4
4
5
5
5
5
5
5
5
6
6
PBT
30
35
36
18
36
15
47
135
35
49
29
40
41
Tax %
26%
26%
26%
25%
26%
72%
26%
13%
26%
25%
24%
26%
26%
Net Profit
22
26
26
13
27
4
35
117
26
37
22
30
31
EPS in Rs
13.36
15.64
16
8.01
16.18
2.54
21.12
70.95
15.9
22.28
13.38
18.08
18.48
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
242
279
294
344
330
376
389
440
513
582
653
708
734
Expenses
228
256
274
306
296
315
318
353
408
453
493
560
579
Operating Profit
14
23
20
38
34
60
71
87
104
129
161
148
155
OPM %
6%
8%
7%
11%
10%
16%
18%
20%
20%
22%
25%
21%
21%
Other Income
1
1
18
1
1
-5
1
3
4
7
95
29
28
Interest
3
2
4
5
5
3
2
1
1
1
2
2
1
Depreciation
11
10
11
14
15
16
16
16
16
17
21
21
22
PBT
1
12
23
20
15
36
54
73
92
118
233
154
160
Tax %
0%
0%
10%
34%
28%
20%
25%
30%
26%
26%
21%
25%
—
Net Profit
1
12
21
13
11
29
40
51
68
88
183
115
119
EPS in Rs
0.6
7.03
12.7
8.13
6.54
17.54
24.19
31.13
40.9
53
111
69.64
72.22
Div. Payout %
132%
23%
22%
30%
37%
23%
30%
31%
29%
30%
22%
34%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
13
13
13
13
13
13
13
13
13
13
13
13
Reserves
112
120
134
142
147
163
203
243
294
362
517
592
Borrowings
33
23
45
54
36
12
2
1
0
0
0
20
Other Liabilities
39
49
55
82
54
78
85
88
112
138
127
168
Total Liabilities
197
205
247
291
251
267
303
345
419
513
658
793
Fixed Assets
105
109
137
131
128
123
113
104
124
114
172
197
CWIP
1
2
2
9
17
10
12
31
25
96
16
23
Investments
0
0
0
0
0
0
0
0
58
91
127
120
Other Assets
92
94
108
152
106
134
178
210
211
212
343
454
Total Assets
197
205
247
291
251
267
303
345
419
513
658
793
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
-2
33
7
15
46
50
58
65
91
94
78
56
Investing
-10
-15
-30
-16
-19
-11
-8
-35
-106
-79
-42
51
Financing
12
-18
23
0
-26
-39
-10
-14
-17
-20
-27
-21
Net Cash Flow
0
0
1
-1
0
0
40
17
-32
-5
9
87
Free Cash Flow
-12
18
-48
-1
26
39
50
41
58
25
151
-9
CFO/OP
14
150
58
48
144
94
94
96
111
96
81
63
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
61
48
49
72
43
62
54
27
27
31
48
60
Inventory Days
149
156
163
171
136
133
162
214
203
200
159
179
Days Payable
109
135
102
165
83
127
132
117
138
140
135
141
Cash Conversion Cycle
101
70
110
78
96
68
84
124
91
90
72
99
Working Capital Days
27
26
20
22
20
41
52
47
33
25
45
64
ROCE %
2%
9%
10%
13%
10%
23%
27%
31%
33%
35%
33%
26%

Shareholding Pattern

As of Jun 2026
Promoters 72.95%
Public 13.88%
DIIs 8.67%
Others 3.54%
FIIs 0.95%
Total 99.99%
  Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
72.07%
72.07%
72.07%
72.07%
72.07%
72.41%
72.61%
72.61%
72.81%
72.81%
72.81%
72.81%
72.81%
72.81%
72.81%
72.95%
72.95%
72.95%
72.95%
72.95%
72.95%
72.95%
FIIs
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.46%
0.56%
0.89%
1.14%
1.35%
1.30%
1.45%
1.35%
1.11%
1.00%
0.87%
0.95%
DIIs
0.01%
0.01%
0.01%
0.01%
0.01%
0.01%
2.04%
2.02%
2.12%
2.29%
3.59%
3.79%
4.19%
4.63%
5.45%
6.06%
6.14%
6.48%
6.70%
7.04%
7.45%
8.67%
Government
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Public
20.45%
20.59%
20.58%
20.65%
20.85%
20.37%
19.91%
20.26%
19.91%
19.45%
18.41%
18.16%
17.41%
16.79%
15.92%
15.58%
15.33%
15.46%
15.37%
15.17%
14.98%
13.88%
Others
7.47%
7.33%
7.34%
7.28%
7.07%
7.21%
5.44%
5.10%
5.16%
5.45%
4.73%
4.67%
4.70%
4.62%
4.47%
4.11%
4.12%
3.76%
3.88%
3.83%
3.74%
3.54%
No. of Shareholders
18,701
20,564
23,674
22,768
22,821
22,115
20,757
21,360
20,837
20,226
21,088
21,866
22,137
22,232
23,481
24,891
24,867
25,832
26,657
25,905
25,282
23,886

Documents

Frequently Asked Questions about RPG Life Sciences Ltd

What does RPG Life Sciences Ltd do?
Incorporated in 2007, RPG Life Sciences Ltd manufactures and markets Formulations (Finished Dosage Forms) and Active Pharma Ingredients[1]
Where is RPG Life Sciences Ltd (RPGLIFE) listed?
RPG Life Sciences Ltd is listed on the Indian stock exchanges. It is listed on NSE: RPGLIFE and BSE: 532983. You can view its live share price, financials, and ratios on Tapetide.
Which sector does RPG Life Sciences Ltd belong to?
RPG Life Sciences Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of RPG Life Sciences Ltd?
RPG Life Sciences Ltd has a market capitalisation of approximately ₹4378.54 Cr. Based on this, it is classified as a Small Cap stock.
What is the PE ratio of RPG Life Sciences Ltd?
The Price-to-Earnings (PE) ratio of RPG Life Sciences Ltd is 36.46. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of RPG Life Sciences Ltd?
Over the past 52 weeks, RPG Life Sciences Ltd has traded between a low of ₹1,733 and a high of ₹3,082. This range helps investors understand the stock's price volatility and recent trading levels.
Does RPG Life Sciences Ltd pay dividends?
Yes, RPG Life Sciences Ltd has a dividend yield of 0.91%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of RPG Life Sciences Ltd?
RPG Life Sciences Ltd has a Return on Equity (ROE) of 19.03%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research RPG Life Sciences Ltd on Tapetide?
On Tapetide, you can view RPG Life Sciences Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Incorporated in 2007, RPG Life Sciences Ltd manufactures and markets Formulations (Finished Dosage Forms) and Active Pharma Ingredients[1]

Website rpglifesciences.com
CEO Mr. Ashok Nair
Employees 1,331
Listed 2008-06-10
Face Value ₹ 8
Issued Size 1,65,39,015

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List